Galapagos is moving from strength to strength as the majority of the agreements signed during 2005-2006 including the deal with GSK have been long-term turnkey contract discovery projects. Moreover BioFocus and DPI acquisition assist Galapagos to become a ‘one-stop shop’ for pharmaceutical and biotechnology companies seeking to subcontract the process of drug development from target identification to lead optimization and proof-of-concept.